Johnson & Johnson (JNJ)
| Market Cap | 376.43B |
| Revenue (ttm) | 89.33B |
| Net Income (ttm) | 21.81B |
| Shares Out | 2.41B |
| EPS (ttm) | 8.98 |
| PE Ratio | 17.41 |
| Forward PE | 14.84 |
| Dividend | $5.20 (3.32%) |
| Ex-Dividend Date | May 27, 2025 |
| Volume | 6,791,312 |
| Open | 155.43 |
| Previous Close | 155.23 |
| Day's Range | 155.02 - 157.44 |
| 52-Week Range | 140.68 - 169.99 |
| Beta | 0.41 |
| Analysts | Buy |
| Price Target | 169.33 (+8.23%) |
| Earnings Date | Jul 16, 2025 |
About JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price forecast is $169.33, which is an increase of 8.23% from the latest price.
News
Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. “We are thrilled to have Da...
Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?
The recent jobs data showed that hiring in healthcare took a big jump in May, as the stock sector has stabilized a bit after years of underperformance.
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity
More than half of patients maintained minimal residual disease (MRD) negativity (10-5) with DARZALEX FASPRO ® for 24 months or longer in the Phase 3 PERSEUS study Data from Phase 3 CEPHEUS study show...
Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients
Phase 1 trial demonstrates encouraging clinical activity of investigational immunotherapy for relapsed or refractory multiple myeloma Novel investigational dual-antigen-targeting immunotherapy binds t...
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma
New long-term CARTITUDE-1 data show one-third of patients treated with CARVYKTI ® remain progression-free CARTITUDE-4 analysis shows compelling overall survival and progression-free benefits in stand...
Johnson & Johnson's AKEEGA® (niraparib and abiraterone acetate dual-action tablet) is the first PARP inhibitor combo to show improved efficacy in patients with HRR-mutated mHSPC vs. current standard of care
Results from the Phase 3 AMPLITUDE study show the potential of niraparib and abiraterone acetate to delay cancer progression and worsening of symptoms1
Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC
Results from the Phase 3 AMPLITUDE study show the potential of AKEEGA® (niraparib and abiraterone acetate dual-action tablet) to delay cancer progression and worsening of symptoms Data show a nearly 5...
June's Top 10 High-Yield Stocks: Build A Path To A 10%+ Yield By 2035
My top 10 high-yield picks for June 2025 balance attractive dividend yields, strong financials, and competitive advantages to reduce risk and enhance returns. I use a rigorous four-step selection proc...
Biotech Bull Case, ABVX International Interest, JNJ & LLY Options Trades
"You cannot not believe in science," says Tsvetta Kaleynska. She sees biotech companies outperforming in 2025 despite a slow start to the year.
'No more tears': Author Gardiner Harris on J&J's controversies over the years
Gardiner Harris, ‘No More Tears' author and former New York Times correspondent, joins 'Squawk Box' to discuss the controversies and challenges facing Johnson & Johnson over the years.
Johnson & Johnson: Relative Stability In A Wild 2025 Stock Market
Johnson & Johnson remains undervalued with strong profitability and reasonable valuation metrics, but growth prospects are modest and uncertain. Profitability is robust, with an A+ grade, high margins...
J&J CEO Joaquin Duato on cancer treatments, M&A outlook and 'most favored nation' policy
CNBC's Angelica Peebles and Johnson & Johnson chairman and CEO Joaquin Duato join 'Squawk Box' to discuss the company's 5-year multiple myeloma treatment study, the company's cancer treatments, M&A ou...
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 16th to review second-quarter results. Joaq...
Johnson & Johnson (JNJ) Presents at the Bernstein's 41st Annual Strategic Decisions Conference (Transcript)
Johnson & Johnson (NYSE:JNJ) Bernstein's 41st Annual Strategic Decisions Conference Call May 28, 2025 9:00 AM ET Company Participants Joaquin Duato - Chairman and Chief Executive Officer Joseph Wolk ...
Johnson & Johnson: Dividend King On Sale Yielding Over 3% And Undervalued
Despite legal headwinds and a declining share price, JNJ remains a financial powerhouse with strong profitability, a robust dividend, and aggressive buybacks. JNJ's 62-year streak of dividend growth, ...
Johnson & Johnson: Raising My Price Target Amid Stable EPS Growth
I maintain my buy rating on JNJ, citing attractive valuation, improved technicals, and a raised intrinsic value target of $184 per share. JNJ's recent earnings beat expectations, with strong Medicine ...
No Rolex For Me - I'm Buying Dividends That Pay For Life
I love luxury watches, but buying more to "earn" access to rarer models made me realize how easy it is to waste capital chasing ego-driven goals. Unlike watches, dividend growth stocks offer reliable ...
FDA Panel Reiterates the Cancer Risks of Talc
WASHINGTON--(BUSINESS WIRE)--A panel of medical experts convened by the U.S. Food & Drug Administration urged the agency to study and adopt new standards to prohibit the use of talc in consumer produc...
Johnson & Johnson to Participate in the Bernstein's 41st Annual Strategic Decisions Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Bernstein's 41st Annual Strategic Decisions Conference on Wednesday, May 28th, 2025. Management will participate...
Forget About Dividend Yield, Do This Instead
Focus on dividend sustainability and business quality, not just high yield, to build reliable passive income. Avoid overexposure to cyclical sectors; prioritize companies with resilient dividends thro...
U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma
ODAC recommendation based on the positive progression-free survival and clinical benefit in the Phase 3 AQUILA study If approved, DARZALEX FASPRO® would be the first treatment to potentially delay or ...
Johnson & Johnson (JNJ) RBC Capital Markets Global Healthcare Conference
Johnson & Johnson (NYSE:JNJ) RBC Capital Markets Global Healthcare Conference May 20, 2025 1:35 PM ET Corporate Participants Joe Wolk - EVP, Chief Financial Officer Conference Call Participants Shagu...
Dean Omar Branham Shirley Recognized Twice Among ALM's 2024 Top 100 Verdicts
DALLAS--(BUSINESS WIRE)--National plaintiffs firm Dean Omar Branham Shirley, LLP, has been recognized by ALM and Law.com for securing two of the largest jury verdicts of 2024. Both cases involved clai...
Moody's U.S. Debt Downgrade: Stocks Poised To Benefit
Corporations play a vital and often benevolent role in capitalist societies, supporting economic growth and innovation with more conservative balance sheets than their governments. Microsoft, Apple an...
Statement On $147M Verdict for AMDR Member Innovative Health Against Johnson & Johnson's Biosense Webster Medical Technology Unit
WASHINGTON & BERLIN--(BUSINESS WIRE)--Association of Medical Device Reprocessors issued the following statement: Friday's unanimous verdict by a federal jury in Santa Ana, California for Innovative He...